Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

uniQure N.V. QURE

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
22.08
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 2 — 2 2 8 — 1 18 1 — —
Insider Ownership
2.69%

Capital & Financial Ratios

Market Cap
3,120.00
Revenue
18.67
Net Income
(252.21)
Free Cash Flow
(161.45)
Net Debt
(760.19)
Current Ratio
10.01
Debt/Equity
0.15
P/E ratio
0.00
P/S ratio
156.10
P/B ratio
8.99
Past 5Y EPS Growth
(9.66%)
This Y EPS Growth
(12.50%)
Next Y EPS Growth
22.15%
Next 5Y EPS Growth
30.01%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 617.89 367.52 622.54 810.34
Receivables 4.19 5.88 5.86 5.78
Inventory 12.02 — — —
Other 2.66 7.61 7.08 7.91
651.85 390.29 655.99 834.27
2023 2024 2025 Q'26
Payables 6.59 7.23 5.17 4.98
ST’ Debt — — — —
Other 28.21 — 12.60 24.24
73.68 40.05 62.92 83.35
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 3.56 5.84 — —
—
’25 1.57 5.26 3.70 5.57
16.10
’24 8.49 11.13 2.29 5.22
27.12
’23 5.33 2.42 1.41 6.69
15.84
’22 1.79 0.50 1.45 102.75
106.48
’21 0.45 463.87 1.99 57.69
524.00
’20 0.10 1.54 1.79 34.09
37.51
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (38.24) (28.58) — —
—
’25 (44.10) (39.89) (16.40) (77.57)
(177.96)
’24 (60.57) (32.71) (36.60) (52.84)
(182.73)
’23 (78.30) (57.00) 38.91 (49.54)
(145.93)
’22 (25.71) (15.68) (48.99) (54.68)
(145.06)
’21 (41.27) 416.48 (40.16) (47.09)
287.96
’20 (32.95) (29.99) (34.71) (37.17)
(134.83)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (38.38) (29.05) — —
—
’25 (44.23) (40.15) (16.33) (77.69)
(178.40)
’24 (62.92) (33.31) (36.98) (52.88)
(186.10)
’23 (80.64) (58.07) 37.21 (51.58)
(153.08)
’22 (29.77) (20.26) (52.98) (59.75)
(162.75)
’21 (45.15) 414.16 (47.85) (50.64)
270.52
’20 (35.84) (31.71) (36.89) (39.87)
(144.31)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.85) (1.22) — —
—
’25 (0.82) (0.69) (1.38) (0.56)
(3.46)
’24 (1.36) (1.16) (0.91) (1.50)
(4.92)
’23 (1.63) (1.44) (1.88) (1.53)
(6.47)
’22 (1.00) (0.84) (1.02) 0.15
(2.71)
’21 (0.91) 8.51 (0.79) 0.17
7.04
’20 (0.63) (0.96) (1.21) (0.01)
(2.81)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 12.52 5.49 3.73 7.76 — — —
Low Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.26 23.46 18.42 71.50 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 501 480 209 221 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.21 0.03 0.13 0.07 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 106.48 15.84 27.12 16.10 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 96.86% 13.98% 32.42% 89.53% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (128.26) (306.56) (237.13) (193.34) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (120.45%) (1,934.97%) (874.39%) (1,201.02%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (126.79) (308.48) (239.56) (198.97) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.54 11.90 12.64 14.76 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.28 0.33 0.56 0.28 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (2.71) (6.47) (4.92) (3.46) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.10) (3.06) (3.76) (3.09) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.38) (0.15) (0.07) (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.48) (3.21) (3.83) (3.10) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.19 4.36 (0.14) 3.46 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 46.74 47.67 48.65 57.50 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.59 20.85 31.68 85.48 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.14 1.59 0.00 6.92 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.32 (11.23) 20.31 50.38 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.72) 1.15 (2.93) (4.49) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (145.06) (145.93) (182.73) (177.96) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (17.69) (7.15) (3.37) (0.44) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (162.75) (153.08) (186.10) (178.40) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 400.86 578.18 350.24 593.07 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 111.17 101.75 51.32 49.70 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (241.67) (516.14) (316.20) (572.84) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 476.01 207.67 (6.75) 198.90 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.75%) (40.15%) (34.51%) (28.81%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.18%) 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (23.66%) (90.24%) (238.46%) (207.10%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

uniQure N.V. (QURE), a clinical-stage biotech pioneer in AAV-based gene therapies for neurological and liver diseases, embodies the gene therapy sector’s high-risk volatility. Buoyed by the 2022 FDA approval of Hemgenix for Hemophilia B in partnership with CSL Behring, the company saw explosive 2021 revenues of $524 million from milestones, but post-approval commercialization struggles, regulatory delays, and a biotech funding drought amid rising rates triggered sharp declines—revenues cratering to $27 million in 2024, with deep losses, collapsing gross margins, aggressive headcount cuts (down 58%), and negative book value signaling survival mode.

Stock prices mirrored these swings, plummeting 91% from 2020 highs to 2024 lows before a modest rebound, trading at elevated EV/Sales multiples amid insider heavy selling (zero buys, $14 million in proceeds from C-suite and board exits in 2025-2026)—a cautionary signal in a sector where execution risks peak post-approval.

Analysts remain bullish, with mean price targets implying 140% upside, forecasting revenue explosions to $200 million by 2027 from Hemgenix royalties, AMT-130 Huntington’s data, and pipeline catalysts, in a gene therapy market eyeing $20B+ by 2030. Yet, this binary bet demands scrutiny of dilution risks, macro tailwinds like Fed cuts, and historical pitfalls—offering asymmetric rewards for patient investors, but short-term caution prevails.

Read full commentary →

uniQure N.V. (QURE) Latest News

News by impact score

Fine-tune

8 Sep

4 , 11:19 PM
uniQure submitted AMT-130 for accelerated approval in Huntington’s disease, raising questions on whether externally controlled data can support the application. AMT-130 submission for accelerated approval marks major regulatory step with potential to reshape uniQure trajectory in Huntington’s disease.

3 Sep

4 , 2:16 PM
uniQure files for AMT-130 approval, indicating the stock may be fully valued. AMT-130 approval filing marks a critical advancement in uniQure's gene therapy pipeline.

4 , 10:30 AM
uniQure N.V. submitted an application for its gene therapy to treat Huntington's Disease. Gene therapy application submission for Huntington's represents a major regulatory advancement for the company.

2 Sep

5 , 7:05 AM
uniQure N.V. submitted a Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) gene therapy in Huntington’s Disease. BLA submission for lead Huntington’s program marks pivotal regulatory step toward potential approval and revenue.

4 , 11:52 AM
UniQure's Huntington's gene therapy clears a key regulatory or clinical hurdle despite prior setbacks. Positive resolution on core Huntington's program directly affects uniQure pipeline value and investor outlook.

3 stocktwits.com, 6:35 PM
uniQure N.V. stock declined following AMT-130 filing. William Blair maintains bullish outlook projecting 58% upside. AMT-130 filing and analyst price target directly affect QURE share price and near-term sentiment.

7 Aug

3 transcript www.fool.com, 8:35 PM
uniQure N.V. (QURE) held its Q2 2026 earnings call discussing quarterly financial results, pipeline progress, and strategic outlook. Earnings call delivers financial metrics and forward guidance that can shift near-term investor sentiment and valuation.

29 Jul

4 www.pharmaceutical-technology.com, 11:49 AM
uniQure expects an FDA Advisory Committee meeting for its Huntington’s disease gene therapy, per the chief medical officer. Expected AdCom review marks key regulatory step for uniQure’s lead Huntington’s gene therapy candidate.

3 , 5:02 PM
uniQure NV (QURE) Q2 2026 earnings call highlighted strategic advances alongside operational challenges. Strategic advances balanced against operational challenges point to moderately noticeable effects on future performance.

3 transcript www.marketbeat.com, 1:04 PM
uniQure N.V. (QURE) presented Q2 earnings call highlights covering financial results, pipeline progress and cash position. Quarterly earnings and pipeline updates can moderately shift near-term sentiment and valuation.

3 , 8:25 AM
uniQure N.V. posted a Q2 loss and missed revenue estimates. Q2 loss and revenue miss signals short-term pressure on financial performance and investor sentiment.

3 , 7:05 AM
uniQure N.V. reported second quarter 2026 financial results and issued a company update. Quarterly results release key performance metrics that can move investor views and share price.

17 Jul

4 , 2:25 PM
uniQure N.V. stock outlook depends on AMT-130 progress, FDA discussions, and cash runway. AMT-130 development, FDA talks, and cash position directly shape QURE trajectory and investor views.

3 , 2:52 PM
Gene therapy investment focus is moving past Hemgenix, creating new trends for uniQure N.V. (QURE) to monitor in its pipeline and competitive positioning. Shift away from Hemgenix signals moderate changes to uniQure's market focus without immediate fundamental disruption.

25 Jun

4 Insider Monkey, 8:41 AM
UniQure N.V. (QURE) received an upgrade to Overweight as its Huntington’s Disease program advances. Analyst upgrade to Overweight on Huntington’s Disease program progress signals major positive shift in investor sentiment and company trajectory.

3 GlobeNewswire, 4:10 PM
uniQure closed its upsized public offering after underwriters fully exercised the option to buy additional shares. The capital raise strengthens uniQure's cash position for ongoing operations without altering core strategy.

23 Jun

3 GlobeNewswire, 9:13 PM
uniQure N.V. priced an upsized public offering of $225 million. Upsized $225 million public offering delivers substantial new capital that moderately affects financial position and share count.

22 Jun

4 Zacks, 10:29 AM
uniQure N.V. (QURE) announced initial data on its gene therapy candidate for temporal lobe epilepsy. Initial data release on new gene therapy program advances uniQure pipeline and signals major future revenue potential.

3 GlobeNewswire, 4:01 PM
uniQure N.V. announces a proposed $150 million public offering. Proposed public offering supplies fresh capital for operations while risking share dilution.

19 Jun

5 , 2:19 PM
uniQure N.V. (QURE) shares surge after FDA backs AMT-130 data for accelerated approval. FDA backing of AMT-130 data for accelerated approval can fundamentally boost uniQure's regulatory path, valuation and long-term prospects.

5 , 1:07 AM
uniQure shares jumped 67.9% after FDA backed AMT-130 data for an accelerated approval path. FDA support for accelerated approval of lead gene therapy candidate AMT-130 fundamentally improves uniQure's regulatory and commercial outlook.

4 , 2:15 AM
uniQure (QURE) stock could be 49% undervalued following FDA update on AMT-130. FDA update on AMT-130 directly boosts uniQure lead asset valuation and long-term trajectory.

3 , 7:05 AM
uniQure announced preliminary data from the first cohort in its Phase I/IIa clinical trial of AMT-260 for refractory mesial temporal lobe epilepsy. Early-stage trial data on AMT-260 may influence uniQure pipeline progress and near-term sentiment.

3 , 6:11 AM
uniQure (QURE) stock fair value lifted on AMT-130 BLA plans despite rework risk. AMT-130 BLA filing plans drive moderate fair value shift for QURE with limited trajectory change.

18 Jun

4 www.barchart.com, 1:32 PM
uniQure received upbeat FDA feedback on its gene therapy programs, signaling accelerated regulatory progress and positioning the stock as drastically undervalued with strong upside potential. Upbeat FDA meeting directly advances uniQure regulatory pathway and materially lifts future revenue prospects.

4 , 11:37 AM
RBC Capital Markets states UniQure's approval path strengthened after positive US FDA feedback. Positive FDA feedback on approval path signals major regulatory progress likely to boost UniQure's trajectory and investor sentiment.

4 www.pharmaceutical-technology.com, 10:57 AM
UniQure plans to seek approval for its Huntington’s gene therapy after FDA reversed prior stance. FDA reversal clears path for uniQure to advance Huntington’s therapy toward approval, materially shifting regulatory and commercial outlook.

4 , 7:30 AM
uniQure (QURE) shares surged 78.4% on positive catalysts, with analysis questioning potential for additional upside. QURE recorded a massive 78.4% single-day gain reflecting major events with strong implications for future performance.

17 Jun

5 , 4:13 PM
uniQure N.V. stock surges nearly 80% after FDA issues unexpected gene therapy decision. FDA shock triggers 80% stock surge signaling transformative regulatory outcome for core gene therapy program.

4 , 8:08 PM
UniQure (QURE) shares surge 78% on progress with AMT-130. AMT-130 progress triggers 78% stock surge signaling major positive shift in company trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us